✦ LIBER ✦

Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer

✍ Scribed by Johnny Kao; Eric M. Genden; Chien-Ting Chen; Michael Rivera; Charles C. L. Tong; Kryztof Misiukiewicz; Vishal Gupta; Vivek Gurudutt; Marita Teng; Stuart H. Packer

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 327 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25786

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1 trial of combined chemotherapy a

Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer

✍ Sharon Spencer; Richard Wheeler; Glenn Peters; Ruby Meredith; Sam Beenken; Lisle 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 2 views

## Abstract ## Background. The management of recurrent unresectable head and neck cancer remains a challenging problem. Based on the circadian rhythm concept, we sought to determine the maximum tolerated dose (MTD) of infusional 5‐flourouracil (5‐FU), hydroxyurea (HU), and reirradiation (RT). ##

Prior chemoradiotherapy adversely impact

Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation

✍ Kevin S. Choe; Daniel J. Haraf; Abhishek Solanki; Ezra E. W. Cohen; Tanguy Y. Se 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 2 views

Toxicity and survival outcomes of hyperf

Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers

✍ John M. Watkins; Keisuke S. Shirai; Amy E. Wahlquist; Robert K. Stuart; Uzair B. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

## Abstract ## __Background__. Reirradiation of locoregionally recurrent, previously irradiated head/neck cancer may be considered in situations of unresectability, medical inoperability, or adverse pathologic features found at salvage resection. ## __Methods__. Retrospective cohort analysis of

Efficacy and toxicity of reirradiation u

Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer

✍ David J. Sher; Robert I. Haddad; Charles M. Norris Jr; Marshall R. Posner; Lori 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 2 views

## Abstract ## BACKGROUND: Patients with locally recurrent squamous cell cancer of the head and neck (SCCHN) are reported to have a poor prognosis and limited therapeutic options. Optimal management is selectively applied and morbid. Both surgical resection and chemoradiotherapy are reported to re

Phase 2 trial of concurrent 5-fluorourac

Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer

✍ Johnny Kao; Eric M. Genden; Vishal Gupta; Edelweiss L. Policarpio; Ryan J. Burri 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB

Toxicity and outcome analysis of patient

Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies

✍ Noel M. Kramer; Eric M. Horwitz; Jonathan Cheng; John A. Ridge; Steven J. Feigen 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

## Abstract ## Background. Patients with local recurrences or new head and neck primary tumors in previously irradiated tissues have few options for salvage treatment. One option for select patients is to undergo reirradiation with concurrent chemotherapy. The purpose of this study is to report th